Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

U.S. Life Sciences Industry Analysis

UpdatedApr 16, 2026
DataAggregated Company Financials
Companies61
  • 7D3.7%
  • 3M-16.9%
  • 1Y14.8%
  • YTD-12.4%

Over the last 7 days, the Life Sciences industry has risen 3.7%, driven by gains from Thermo Fisher Scientific of 5.6%. In the last 12 months, the industry was up 15%. As for the next few years, earnings are expected to grow by 19% per annum.

Industry Valuation and Performance

Has the U.S. Life Sciences Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Fri, 17 Apr 2026US$592.0bUS$147.8bUS$14.1b38.9x42x4x
Sun, 15 Mar 2026US$536.1bUS$147.8bUS$14.0b34.3x38.3x3.6x
Tue, 10 Feb 2026US$618.0bUS$147.4bUS$12.9b36.4x48.1x4.2x
Thu, 08 Jan 2026US$701.7bUS$145.8bUS$12.4b37.1x56.8x4.8x
Sat, 06 Dec 2025US$666.1bUS$145.8bUS$12.5b35.7x53.4x4.6x
Mon, 03 Nov 2025US$648.1bUS$145.4bUS$12.2b36x53.3x4.5x
Wed, 01 Oct 2025US$552.4bUS$144.3bUS$14.6b30.2x38x3.8x
Fri, 29 Aug 2025US$578.9bUS$144.3bUS$14.6b29x39.8x4x
Sun, 27 Jul 2025US$585.5bUS$143.7bUS$8.8b40.1x66.5x4.1x
Tue, 24 Jun 2025US$521.0bUS$142.9bUS$9.2b35.3x56.8x3.6x
Thu, 22 May 2025US$522.0bUS$142.8bUS$9.1b32.1x57.4x3.7x
Sat, 19 Apr 2025US$504.0bUS$142.6bUS$10.0b34.3x50.6x3.5x
Mon, 17 Mar 2025US$597.5bUS$143.1bUS$9.8b38.6x61.2x4.2x
Wed, 12 Feb 2025US$643.4bUS$143.2bUS$11.1b37.2x57.7x4.5x
Fri, 10 Jan 2025US$677.6bUS$142.4bUS$10.2b43.7x66.4x4.8x
Sun, 08 Dec 2024US$664.3bUS$142.4bUS$10.2b44.2x65x4.7x
Tue, 05 Nov 2024US$689.5bUS$142.3bUS$9.0b39.1x76.8x4.8x
Thu, 03 Oct 2024US$752.7bUS$141.8bUS$8.5b39.3x88.6x5.3x
Sat, 31 Aug 2024US$746.6bUS$141.8bUS$8.5b37.8x87.9x5.3x
Mon, 29 Jul 2024US$732.9bUS$141.0bUS$12.6b37.3x58.3x5.2x
Wed, 26 Jun 2024US$696.3bUS$141.3bUS$12.2b38.2x57.2x4.9x
Fri, 24 May 2024US$735.1bUS$141.5bUS$12.4b38.7x59.2x5.2x
Sun, 21 Apr 2024US$681.6bUS$142.0bUS$12.8b40.8x53.3x4.8x
Tue, 19 Mar 2024US$742.5bUS$142.1bUS$12.8b44.3x57.8x5.2x
Thu, 15 Feb 2024US$697.5bUS$142.2bUS$12.8b43x54.3x4.9x
Sat, 13 Jan 2024US$684.9bUS$153.9bUS$14.2b35.4x48.3x4.5x
Mon, 11 Dec 2023US$644.8bUS$153.7bUS$14.0b35.2x46x4.2x
Wed, 08 Nov 2023US$590.2bUS$153.9bUS$11.0b30.9x53.6x3.8x
Fri, 06 Oct 2023US$642.5bUS$154.6bUS$11.2b33x57.4x4.2x
Sun, 03 Sep 2023US$735.8bUS$154.6bUS$11.2b33.1x65.7x4.8x
Tue, 01 Aug 2023US$727.5bUS$154.7bUS$11.6b31.1x62.6x4.7x
Thu, 29 Jun 2023US$680.9bUS$152.4bUS$12.5b29.5x54.4x4.5x
Sat, 27 May 2023US$677.4bUS$152.2bUS$12.5b27.7x54.2x4.5x
Mon, 24 Apr 2023US$728.5bUS$154.6bUS$10.8b29.9x67.4x4.7x
Price to Earnings Ratio

67.4x


Total Market Cap: US$728.5bTotal Earnings: US$10.8bTotal Revenue: US$154.6bTotal Market Cap vs Earnings and Revenue0%0%0%
U.S. Life Sciences Industry Price to Earnings3Y Average 57.3x202420252026
Current Industry PE
  • Investors are pessimistic on the American Life Sciences industry, indicating that they anticipate long term growth rates will be lower than they have historically.
  • The industry is trading at a PE ratio of 42.0x which is lower than its 3-year average PE of 57.3x.
  • The 3-year average PS ratio of 4.5x is higher than the industry's current PS ratio of 4.0x.
Past Earnings Growth
  • The earnings for companies in the Life Sciences industry have grown 9.3% per year over the last three years, while revenues have remained mostly flat.
  • This means that companies overall are more efficiently conducting business since profits are increasing while sales have been flat.

Industry Trends

Which industries have driven the changes within the U.S. Healthcare industry?

US Market3.42%
Healthcare-0.18%
Life Sciences3.71%
Clinical Research and Equipment3.71%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
TMO Thermo Fisher ScientificUS$516.003.1%
+US$5.8b		20.7%PE28.6x
TEM Tempus AIUS$54.4223.2%
+US$1.8b		34.5%PS7.7x
ILMN IlluminaUS$132.727.3%
+US$1.4b		86.4%PE23.7x
WST West Pharmaceutical ServicesUS$269.814.4%
+US$811.7m		33.6%PE39.4x
A Agilent TechnologiesUS$118.252.5%
+US$808.2m		15.4%PE25.9x

Latest News

IQV
US$171.95
IQVIA Holdings
7D
1.8%
1Y
19.5%

IQV: Data And Clinical Trial Scale Will Support Earnings Reacceleration

The analyst price target for IQVIA Holdings has been reset from $250.00 to $231.60 as analysts factor in updated models after recent Q4 results, AI related uncertainties, and broader sector target cuts, while still highlighting the company’s data and clinical trial capabilities in several upgraded ratings. Analyst Commentary Recent research updates on IQVIA show a mix of optimism around the company’s data assets and clinical trial exposure, alongside caution as models are reset after Q4 results and AI related questions.
ILMN
US$132.72
Illumina
7D
7.3%
1Y
86.4%

ILMN: Future Returns Will Depend On Pricing Power And 2026 Tools Demand

Analysts have kept the fair value estimate for Illumina steady at $136.11 per share, with a mix of recent price target increases and trims reflecting updated views on growth, profitability, and competitive pricing after Roche's latest genome sequencing announcement. Analyst Commentary Recent research suggests that views on Illumina are mixed, with the Roche Axelios pricing helping sentiment while target changes reflect different views on execution risk and growth visibility.
QGEN
US$40.96
Qiagen
7D
-0.1%
1Y
-4.4%
TMO
US$516.00
Thermo Fisher Scientific
7D
3.1%
1Y
20.7%
TEM
US$54.42
Tempus AI
7D
23.2%
1Y
34.5%

TEM: Data Partnerships And Backlog Will Support Future Precision Oncology Leadership

Narrative Update on Tempus AI The updated analyst price target for Tempus AI moves to $72.73 from $77.93, as analysts factor in slightly higher discount rates and a lower future P/E multiple. They still point to ongoing partnerships and data backlog as key supports for the long term story.
TKNO
US$2.68
Alpha Teknova
7D
-3.9%
1Y
-53.5%

TKNO: Long Term Revenue Guidance And Higher P/E Will Support Future Upside

Analysts have adjusted their price target on Alpha Teknova to $7.00 from $7.00, reflecting updated views on discount rate, revenue growth, profit margin and future P/E assumptions. What's in the News Alpha Teknova issued revenue guidance for the fiscal year ending December 31, 2026, indicating an expected total revenue range of $42 million to $44 million.
RVTY
US$89.53
Revvity
7D
-1.0%
1Y
-2.5%
MTD
US$1,290.84
Mettler-Toledo International
7D
-3.3%
1Y
28.4%

MTD: Extensive Buybacks And 2026 Sales Outlook Will Support Future Upside

Analysts have trimmed their price target for Mettler-Toledo International by about $7 to $1,498, reflecting small adjustments to fair value, discount rate, revenue growth and profit margin assumptions, along with a slightly lower future P/E estimate. What's in the News Mettler-Toledo International reported completion of a long running share repurchase program first announced on February 9, 2010, having bought back a total of 17,805,987 shares, or 66.06%, for US$9,514.61m under the authorization.
WST
US$269.81
West Pharmaceutical Services
7D
4.4%
1Y
33.6%
A
US$118.25
Agilent Technologies
7D
2.5%
1Y
15.4%

A: New Diagnostic Expansion And Guidance Will Support Long Term Upside

Analysts have slightly reduced their price target on Agilent Technologies by about $1, citing updated assumptions for fair value, discount rate, revenue growth, profit margin, and future P/E. They indicate that the overall outlook remains largely intact.
ICLR
US$115.58
ICON
7D
8.3%
1Y
-17.0%

ICLR: Accounting Review And Backlog Uncertainty Will Pressure Earnings Quality And Sentiment

Narrative update on ICON analyst targets Analysts have collectively reset ICON's average price target lower to around $120, citing ongoing accounting investigations and reduced sector targets. Some also highlight the possibility of upside if biopharma activity improves and current valuation already reflects much of the perceived risk.
DHR
US$193.78
Danaher
7D
0.4%
1Y
3.7%

Danaher: A Great Way To Play Healthcare For Long-Term Dividend Growth Investors

Apr 06
CTKB
US$4.61
Cytek Biosciences
7D
-0.2%
1Y
26.3%

CTKB: 2026 Guidance And Buyback Will Frame Balanced Multi Year Upside Potential

Narrative Update Analysts have lifted their price target on Cytek Biosciences to $5 from $4, pointing to a clearer multi year framework and several potential growth drivers as key reasons for the change. Analyst Commentary Analysts highlighting the higher US$5 price target frame Cytek Biosciences as a name that could benefit if the broader diagnostic tools group sees improving sentiment and clearer multi year guidance.
ATLN
US$1.97
Atlantic International
7D
-36.7%
1Y
-49.7%
CDT
US$3.53
CDT Equity
7D
-40.1%
1Y
-99.8%
BNBX
US$0.58
BNB Plus
7D
-6.8%
1Y
-95.3%